Completed
Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1)
What is being tested
Data Collection
Who is being recruted
Hematologic Diseases+9
+ Hemic and Lymphatic Diseases
+ Immune System Diseases
From 15 to 65 Years
+9 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 4
Interventional
Study Start: April 2004
Summary
Principal SponsorJohann Wolfgang Goethe University Hospital
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: April 1, 2004
Actual date on which the first participant was enrolled.This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to a protocol for acute lymphoblastic leukemia. Patients receive one year of intensive cyclical chemotherapy with additional prophylaxis for central nervous system (CNS) relapse by intrathecal therapy and cranial irradiation and mediastinal irradiation after induction chemotherapy.
Official TitleMulticenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1)
Principal SponsorJohann Wolfgang Goethe University Hospital
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
75 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 15 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Hematologic DiseasesHemic and Lymphatic DiseasesImmune System DiseasesImmunoproliferative DisordersLeukemiaLeukemia, LymphoidLymphatic DiseasesLymphomaLymphoproliferative DisordersNeoplasmsNeoplasms by Histologic TypePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Criteria
3 inclusion criteria required to participate
T-lymphoblastic lymphoma (bone marrow [BM] involvement < 25%)
Aged 15-65 years (55-65 years if biologically younger)
Written informed consent
6 exclusion criteria prevent from participating
Severe complications due to lymphoma or secondary disease
T-LBL as second malignancy or other active second malignancy
Cytostatic pretreatment of LBL (exception of emergency treatments)
Pregnancy
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
University Hospital, Medical Dept. II
Frankfurt, GermanyOpen University Hospital, Medical Dept. II in Google MapsCompletedOne Study Center